Viiv Hlthcare Company Profile

✉ Email this page to a colleague

VIIV HLTHCARE has twenty-six approved drugs.

There are twelve US patents protecting VIIV HLTHCARE drugs.

There are five hundred and fourteen patent family members on VIIV HLTHCARE drugs in fifty-nine countries and two hundred and eleven supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021		RX	Yes	Yes	8,410,103	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Viiv Hlthcare	SELZENTRY	maraviroc	SOLUTION;ORAL	208984-001	Nov 4, 2016		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RETROVIR	zidovudine	TABLET;ORAL	020518-002	Oct 4, 1996	4,724,232	⤷ Try a Trial
Viiv Hlthcare	ZIAGEN	abacavir sulfate	SOLUTION;ORAL	020978-001	Dec 17, 1998	6,294,978*PED	⤷ Try a Trial
Viiv Hlthcare	LEXIVA	fosamprenavir calcium	SUSPENSION;ORAL	022116-001	Jun 14, 2007	6,436,989*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Solution	20 mg/ml	➤ Subscribe	2012-12-27
➤ Subscribe	Tablets	150 mg/300 mg	➤ Subscribe	2007-06-26
➤ Subscribe	Tablets	10 mg, 25 mg and 50 mg	➤ Subscribe	2017-08-14
➤ Subscribe	Tablets	300 mg/150 mg/300 mg	➤ Subscribe	2011-03-22
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2011-11-22
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2009-01-28
➤ Subscribe	Tablets	700 mg	➤ Subscribe	2012-01-18
➤ Subscribe	Tablets	600 mg/300 mg	➤ Subscribe	2007-09-27
➤ Subscribe	Tablets	600 mg/50 mg/300 mg	➤ Subscribe	2017-08-14
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2011-08-08

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	30/2014	Austria	⤷ Try a Trial	PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DOLUTEGRAVIR-NATRIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 (MITTEILUNG) 20140121
0933372	PA2008006	Lithuania	⤷ Try a Trial	PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
1663240	2015/054	Ireland	⤷ Try a Trial	PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.